Femasys

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Femasys sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials 1 currently recruiting 3 completed upper quartile by trial count

Femasys: 5 sponsored US clinical trials, 1 recruiting.

Femasys sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. The most-studied condition in this pipeline is Contraception, with 4 trials.

Upper-quartile sponsor footprint

Femasys sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

5 total, page 1 of 1

RECRUITING NA

Prospective Multi-Center Trial for FemBloc Permanent Birth Control

NCT05977751
ACTIVE NOT RECRUITING NA

FemBloc® Permanent Contraception - Confirmation Feasibility Trial

NCT04273594
COMPLETED NA

FemaSeed LOCAL Artificial Insemination Trial

NCT04968847
COMPLETED NA

FemBloc® Permanent Contraception - Early Pivotal Trial

NCT03433911
COMPLETED NA

Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception

NCT03067272

Therapeutic Areas

Contraception 4

What is open in the Femasys pipeline

1 recruiting of 5 indexed (20% open); 3 completed (60%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Contraception (4 trials), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Femasys: open-pipeline peers nationwide

Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

Femasys sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4.95.05.055.05.05.1 0%5%10%15%20%25% Total trials Recruiting share Femasys4YouandMeAbbott Rapid DxAccess Business GroupAcera SurgicalAlign TechnologyAltruBioAlvernia UniversityAmazentis
Femasys sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Femasys sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Femasys page

5 registered trials is a research-attention snapshot, not an endorsement of Femasys or any single study.

  • 1 of Femasys's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Contraception is the condition Femasys studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Contraception trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Femasys pipeline card: 5 registered trials from official public datasets.Report a data error.